Adverum Biotechnologies is a clinical-stage leader in the gene therapy space, specifically targeting prevalent ocular diseases that impact millions. By leveraging a proprietary intravitreal (IVT) platform, the company is changing the standard of care by developing durable, single-administration therapies that can be delivered in a standard office setting, effectively removing the need for burdensome, frequent ocular injections.
As a wholly owned subsidiary of Eli Lilly and Company, Adverum combines the agility of a biotech innovator with the resources and reach of a global pharmaceutical leader. Their team is united by a singular, life-changing mission: to restore vision and prevent blindness, offering new hope to patients worldwide.